“Breast Cancer Talk”: Nursing Perspectives on HER2-Targeted Agents in Breast Cancer - Episode 4

Management of Adverse Effects in R/R HER2+ mBC

September 23, 2020
Madelaine Kuiper, NP, UCLA Santa Monica Hematology/Oncology

Loyda E. Braithwaite, NP, University of Wisconsin Carbone Cancer Center

Susan Hays, ANP, Washington University Siteman Cancer Center

Elahe Salehi, DNP, ANP-BC, Dana-Farber Cancer Institute

Counseling patients and the management of adverse effects of newer regimens in relapsed/refractory HER2+ metastatic breast cancer as well as advice for oncology nurses.